文献速递骨质疏松与代谢性骨病创伤骨科

质子泵抑制剂使用与卒中患者骨质疏松及骨折风险:一项基于人群的队列研究

Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
PubMed 文献 · Osteoporos Int · 2017-10-14

该研究利用台湾全民健康保险研究数据库,纳入2000至2012年新诊断卒中患者,经倾向评分匹配后共10596例,PPI使用者与非使用者各5298例。结果显示卒中后PPI使用与骨质疏松、髋部骨折及椎体骨折风险升高相关,调整后HR为1.28(P<0.001),且风险随PPI累积剂量增加呈上升趋势。

要点

  • 卒中后使用PPI与骨质疏松、髋部骨折、椎体骨折风险升高相关,aHR为1.28(P<0.001)。
  • PPI累积剂量1-90、91-365、>365 cDDDs的aHR分别为1.22、1.27、1.66(P均<0.001)。
  • 最高剂量组骨质疏松aHR 1.79、髋部骨折aHR 1.41、椎体骨折aHR 1.82。

核心结论

  • 卒中患者使用PPI与骨质疏松、髋部骨折和椎体骨折风险升高相关,且风险随PPI累积剂量增加而增加。

研究设计与样本

  • 基于台湾全民健康保险研究数据库的基于人群的倾向评分匹配回顾性队列研究,纳入2000至2012年新诊断卒中患者,匹配后共10596例,PPI使用者与非使用者各5298例。

主要发现

  • 卒中后PPI使用与骨质疏松、髋部骨折或椎体骨折复合风险升高相关,aHR为1.28(P<0.001)。
  • 各结局aHR分别为骨质疏松1.26(P<0.001)、髋部骨折1.18(P=0.048)、椎体骨折1.33(P<0.001)。
  • 任何事件(骨质疏松/髋部骨折/椎体骨折)的aHR在PPI累积剂量1-90、91-365、>365 cDDDs分别为1.22(P<0.001)、1.27(P<0.001)、1.66(P<0.001)。
  • 最高剂量组各结局aHR分别为骨质疏松1.79(P<0.001)、髋部骨折1.41(P=0.039)、椎体骨折1.82(P<0.001)。
  • 年龄和性别分层分析显示相似的模式。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A considerable proportion of stroke survivors are prescribed with proton pump inhibitors (PPIs). Our study indicated that PPI use is associated with an increased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients. The risk tends to increase as the cumulative doses of PPIs increase. INTRODUCTION: A considerable proportion of stroke survivors are prescribed with proton pump inhibitors (PPIs). Our study investigated the association between PPI use and the risk of osteoporosis and fracture among stroke survivors. METHODS: A population-based propensity-matched retrospective cohort study was conducted using the National Health Insurance Research Database in Taiwan. Patients diagnosed with a new stroke between 2000 and 2012 were identified. After propensity score matching, 10,596 patients were enrolled, and 5298 patients were each assigned to the PPI user and non-user groups. Hazard ratios (HRs) were calculated for the risk of osteoporosis, hip fracture, and vertebral fractures according to PPI use or non-use. Sensitivity analyses were conducted to evaluate the dose effects of PPI. RESULTS: PPI use after stroke was associated with an increased risk of osteoporosis, hip fracture, or vertebral fracture, with an adjusted HR (aHR) of 1.28 (P < 0.001). The aHRs were also significant for each outcome: osteoporosis, 1.26 (P < 0.001); hip fracture, 1.18 (P = 0.048); vertebral fracture, 1.33 (P < 0.001). A pattern of dose effect was identified. For any event (osteoporosis/hip fracture/vertebral fracture), the aHR for PPI use of 1-90, 91-365, and > 365 cDDDs was 1.22 (P < 0.001), 1.27 (P < 0.001), and 1.66 (P < 0.001), respectively. For each outcome, the highest dose was associated with the highest risk, with aHR of 1.79 (P < 0.001), 1.41 (P = 0.039), and 1.82 (P < 0.001) for osteoporosis, hip fracture, and vertebral fracture, respectively. Age- and sex-stratified analyses revealed similar patterns. CONCLUSIONS: PPI use is associated with an increased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Lin SM, Yang SH, Liang CC, et al. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2017. PMID: 29032384. doi:10.1007/s00198-017-4262-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。